Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + gemcitabine + oxaliplatin + tyrosine kinase inhibitor
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of adebrelimab (a PD-L1 inhibitor), gemcitabine and oxaliplatin (GEMOX chemotherapy regimen), and a tyrosine kinase inhibitor (TKI). The combination is being investigated in open-label, single-arm clinical studies for the first-line treatment of advanced biliary tract cancer. Adebrelimab is a PD-L1 inhibitor that blocks the PD-1/PD-L1 pathway, preventing cancer cells from evading immune detection. GEMOX is a standard chemotherapy combination, while TKIs target specific enzymes involved in cancer cell growth and division.
- Brand names
- Airuika
- Other names
- adebrelimab + GEMOX + TKI
02
Targets
DNACD274 (Programmed cell death protein 1 ligand 1)Tyrosine kinase
Beyond the preview
Go deeper on adebrelimab + gemcitabine + oxaliplatin + tyrosine kinase inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + gemcitabine + oxaliplatin + tyrosine kinase inhibitor.